Reviva Pharmaceuticals Holdings (RVPH) Total Current Liabilities (2018 - 2026)

Reviva Pharmaceuticals Holdings has reported Total Current Liabilities for 9 years, with the latest figure at $6.1 million in Q1 2026.

• Quarterly Total Current Liabilities fell 46.83% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 46.83% YoY) and the FY2025 annual result came in at $7.3 million, down 50.17% from the prior year.
• Total Current Liabilities retreated to $6.1 million in Q1 2026 per RVPH's latest filing, from $7.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $17.5 million in Q3 2024 and troughed at $3.6 million in Q1 2022.
• A 5-year average of $11.2 million and a median of $11.5 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities jumped 555.17% in 2022, then plunged 50.17% in 2025.
• Over 5 years, Total Current Liabilities stood at $10.0 million in 2022, then soared by 72.41% to $17.2 million in 2023, then declined by 14.98% to $14.6 million in 2024, then slumped by 50.17% to $7.3 million in 2025, then dropped by 15.89% to $6.1 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $6.1 million, $7.3 million, and $9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.